Skip to main content

Dr. Michael A. Danso, M.D.

Hematology & Oncology (Hematology & Oncology Physician)

  • Medicare participating

At a glance

Years since graduation
30
In the NPI registry since
2005
Medicare patients seen, 2024
878

The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is

Education and training

  • 2005Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier

Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).

Specialties and state licenses

  • Hematology & Oncology Physician primary
    VA license 0101241940

As reported to the NPI registry. To confirm a license is current, check the state medical board.

Map: Hematology & Oncology per capita by county →

Where they work

Hospitals

Medical groups

Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.

Medicare patients and services

Medicare patients, 2024
878
Services billed
137,065
Patients’ average age
74
Most frequent Medicare services, 2023
ServiceTimesPatients
Injection, pembrolizumab, 1 mg18,80028
Injection, aprepitant, 1 mg12,61036
Injection, paclitaxel, 1 mg10,42219
Injection, denosumab, 1 mg9,96057
Injection, darbepoetin alfa, 1 microgram (non-esrd use)7,64015
Injection, fosaprepitant, 1 mg4,05012
Injection, docetaxel, 1 mg3,23011
Injection, dexamethasone sodium phosphate, 1 mg2,71682
Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count2,023539
Injection, palonosetron hcl, 25 mcg1,68053

Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.

Medicare prescriptions

Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.

Payments from drug and device companies

In 2025, 8 companies reported 16 payments worth $9,090 in total to this clinician.

By type
Consulting Fee$7,943
Food and Beverage$696
Travel and Lodging$301
Compensation for services other than consulting (speaking, faculty)$150

What the payments were for

Largest payments other than meals
DateCompanyWhat it was forAmount
Jul 14, 2025AstraZeneca Pharmaceuticals LP
Jul 14, 2025
Consulting Fee$2,680
Nov 18, 2025AstraZeneca Pharmaceuticals LP
Nov 18, 2025
Consulting Fee$2,010
Nov 13, 2025AstraZeneca Pharmaceuticals LP
Nov 13, 2025
Consulting Fee
DATROWAY · Oncology
$1,340
Nov 6, 2025Genentech USA, Inc.
Nov 6, 2025
Consulting Fee$803
Mar 11, 2025AstraZeneca UK Limited
Mar 11, 2025
Consulting Fee$555
Jan 6, 2025AstraZeneca UK Limited
Jan 6, 2025
Consulting Fee$555
Jul 24, 2025Merck Sharp & Dohme LLC
Jul 24, 2025
Travel and Lodging
KEYTRUDA · ONCOLOGY · travel to Philadelphia, PA · in-kind
$301
Jul 19, 2025Array Biopharma Inc
Jul 19, 2025
Compensation for services other than consulting (speaking, faculty)
LORBRENA; BRAFTOVI; MEKTOVI · ONCOLOGY
$150

Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.

From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.

Who received the most in Virginia →

Industry-funded research

Named as a principal investigator on 27 industry-funded studies in 2025, from 10 companies. The companies reported $1,946,643 in research payments for these studies, mostly to the institutions running them.

  • A Phase III, Open-label, Randomised Study of Neoadjuvant Datopotamab Deruxtecan (Dato DXd) Plus Durvalumab Followed by Adjuvant Durvalumab With or Without Chemotherapy Versus Neoadjuvant Pembrolizumab Plus Chemotherap…
    AstraZeneca Pharmaceuticals LP
  • Phase III Study of Trastuzumab Deruxtecan (T-DXd) with or without Pertuzumab versus Taxane Trastuzumab and Pertuzumab in HER2-positive First-line Metastatic Breast Cancer (DESTINY-Breast09)
    AstraZeneca Pharmaceuticals LP
  • A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer
    Jazz Pharmaceuticals Inc.
  • A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer
    Eli Lilly and Company · Active, not recruiting · NCT05514054
  • A Phase III, Open-label, Randomised Study of Datopotamab Deruxtecan (Dato-DXd) With or Without Durvalumab Compared with Investigators Choice of Chemotherapy (Paclitaxel, Nab-paclitaxel or Gemcitabine + Carboplatin) in…
    AstraZeneca Pharmaceuticals LP
  • A phase III trial of GDC 9545 in combination with palbo in HR HER2 neg 1L mBC
    Genentech, Inc.
  • Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC
    Genentech, Inc.
  • A Phase 3 Open-label, Randomised Study of Datopotamab Deruxtecan?(DatoDXd) With or Without Durvalumab Versus Investigators Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Who Have Residual…
    AstraZeneca Pharmaceuticals LP
  • A Phase 2, Randomized, Multicenter, Open-label Neoadjuvant Study Evaluating Zanidatamab in Combination With Chemotherapy in Participants With HER2-positive Breast Cancer
    Jazz Pharmaceuticals Inc.
  • A Phase 3, Randomized, Open-label Study Comparing Efficacy and Safety of Sacituzumab Tirumotecan sac-TMT, MK-2870 as a Monotherapy and in Combination with PembrolizumabMK-3475 Versus Treatment of Physician's Choice in…
    Merck Sharp & Dohme LLC

From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.

Other Hematology & Oncology clinicians in Norfolk

Sources

NPI registry (CMS NPPES, November 2026; record last updated September 22, 2014), Medicare Care Compare, Medicare Physician & Other Practitioners (2024), Medicare Part D Prescribers (2024) and Open Payments (2025). Information is self-reported or billed data and may be out of date; call before visiting.

NPI 1467445999. Official NPI registry record (opens in a new tab). Clinicians can correct their information in NPPES; changes appear here after our next monthly update.